Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
Garde-Noguera J, Martin-Martorell P, De Julián M, Perez-Altozano J, Salvador-Coloma C, García-Sanchez J, Insa-Molla A, Martín M, Mielgo-Rubio X, Marin-Liebana S, Blasco-Cordellat A, Blasco-Molla S, Gironés R, Marquez-Medina D, Aparisi F, Cerda MCB, Macia-Escalante S, Sánchez A, Juan-Vidal O. Garde-Noguera J, et al. Among authors: aparisi f. Clin Transl Oncol. 2018 Aug;20(8):1072-1079. doi: 10.1007/s12094-017-1829-5. Epub 2018 Jan 24. Clin Transl Oncol. 2018. PMID: 29368144
Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
Garde-Noguera J, Martin-Martorell P, De Julián M, Perez-Altozano J, Salvador-Coloma C, García-Sanchez J, Insa-Molla A, Martín M, Mielgo-Rubio X, Marin-Liebana S, Blasco-Cordellat A, Blasco-Molla S, Gironés R, Marquez-Medina D, Aparisi F, Cerda MCB, Macia-Escalante S, Sánchez A, Juan-Vidal O. Garde-Noguera J, et al. Among authors: aparisi f. Clin Transl Oncol. 2018 Aug;20(8):1096. doi: 10.1007/s12094-018-1916-2. Clin Transl Oncol. 2018. PMID: 29987667
Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
Zhang F, Ferrero M, Dong N, D'Auria G, Reyes-Prieto M, Herreros-Pomares A, Calabuig-Fariñas S, Duréndez E, Aparisi F, Blasco A, García C, Camps C, Jantus-Lewintre E, Sirera R. Zhang F, et al. Among authors: aparisi f. Cancers (Basel). 2021 May 21;13(11):2514. doi: 10.3390/cancers13112514. Cancers (Basel). 2021. PMID: 34063829 Free PMC article.
High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
Muñoz-Unceta N, Zugazagoitia J, Manzano A, Jiménez-Aguilar E, Olmedo ME, Cacho JD, Oliveira J, Dómine M, Ortega-Morán L, Aguado C, Luna AM, Fernández L, Pérez J, Font C, Salvador C, Corral J, Benítez G, Ros S, Biosca M, Calvo V, Martínez J, Sánchez-Cánovas M, López R, Sereno M, Mielgo X, Aparisi F, Carmona M, Carrión R, Ponce-Aix S, Soares M, Martínez-Salas I, García-Morillo M, Juan-Vidal O, Blasco A, Muñoz AJ, Paz-Ares L; Grupo de trombosis y cáncer SEOM. Muñoz-Unceta N, et al. Among authors: aparisi f. Eur J Cancer. 2020 Dec;141:193-198. doi: 10.1016/j.ejca.2020.10.002. Epub 2020 Nov 7. Eur J Cancer. 2020. PMID: 33166862
Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients.
Dong N, Moreno-Manuel A, Calabuig-Fariñas S, Gallach S, Zhang F, Blasco A, Aparisi F, Meri-Abad M, Guijarro R, Sirera R, Camps C, Jantus-Lewintre E. Dong N, et al. Among authors: aparisi f. Cancers (Basel). 2021 Jun 12;13(12):2950. doi: 10.3390/cancers13122950. Cancers (Basel). 2021. PMID: 34204662 Free PMC article.
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D, García-Campelo R, Del Barco E, Juan O, Aparisi F, González-Larriba JL, Domine M, Trigo JM, Cobo M, Cerezo S, Calzas J, Massutí B, Bosch-Barrera J, García Coves P, Domènech M, Provencio M. Franco F, et al. Among authors: aparisi f. PLoS One. 2021 Jun 2;16(6):e0251761. doi: 10.1371/journal.pone.0251761. eCollection 2021. PLoS One. 2021. PMID: 34077442 Free PMC article.
Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial.
Juan Ó, Aparisi F, Sánchez-Hernández A, Muñoz-Langa J, Esquerdo G, García-Sánchez J, López A, Garde J, Giner V. Juan Ó, et al. Among authors: aparisi f. Clin Lung Cancer. 2015 May;16(3):193-9. doi: 10.1016/j.cllc.2014.11.006. Epub 2014 Nov 23. Clin Lung Cancer. 2015. PMID: 25547902 Clinical Trial.
48 results